Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers

Cells(2024)10.3390/cells13242087Source: DataRank Database

Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers is a research paper published in Cells (2024). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

geo gen nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 0.18)OA: goldTopics (37)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Chuling Zhuang ORCID,Mariana K. Najjar ORCID,Grace L. Wong ORCID,Shivani Bindal ORCID,Kounosuke Watabe ORCID

Live enrichment

PubMed:39768178 PMC:PMC11674475 OpenAlex:https://openalex.org/W4405495435

Department of Defense

Grant: W81XWH-17-1-0044

NIH HHS

Grant: 1R21CA286225-01A1

NCI NIH HHS

Grant: R21 CA286225

Department of Defense

Grant: HT9425-24-1-0889

Department of Defense

Grant: W81XWH-19-1-0753

Department of Defense

Grant: W81XWH-20-1-0044

NIH HHS

Grant: 1R01CA228137-05A1

NCI NIH HHS

Grant: R01 CA228137

MetaVivor

Grant: Translational Research Grant

Department of Defense

Grant: W81XWH-19-1-0072

FWCI

0.18

Citation Percentile

0.6%

Citation Trend

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/2073-4409/13/24/2087/pdf?version=1734446960

journalhttps://doi.org/10.3390/cells13242087

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39768178

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11674475

repositoryhttps://digitalcommons.library.tmc.edu/uthmed_docs/3507

Fields of Study

Cancer-related Molecular PathwaysCytokine Signaling Pathways and InteractionsChemokine receptors and signaling

MeSH Terms

AnimalsDrug SynergismFemaleHumansIndolesKetoconazoleNeoplasm MetastasisSignal TransductionReceptor, ErbB-2Erb-b2 Receptor Tyrosine KinasesXenograft Model Antitumor AssaysCell Line, TumorCell ProliferationSTAT3 Transcription FactorCytokine Receptor gp130MiceTriple Negative Breast Neoplasms

Keywords

Cancer researchTriple-negative breast cancerBreast cancerMedicineMetastasisCancerInternal medicinegp130IL-6Stat3Combination therapyKetoconazoleBazedoxifeneTgli1TnbcHer2-enriched Breast CancerBreast Cscs

Sustainable Development Goals

SDG 0: Good health and well-being

Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers

FAIR Checklist

Authors (8)

Funding (10 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)